Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors

26 Sept 2019

Abstract excerpt

Abstract Purpose: Human telomerase reverse transcriptase (hTERT) is highly expressed in >85% of human tumors and is thus considered as a good tumor-associated antigen candidate for vaccine development. We conducted a phase I study to investigate the safety, tolerability, clinical response, and immunogenicity of INVAC-1, a DNA plasmid encoding a modified hTERT protein in patients with relapsed or refractory solid...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immunotherapy and Immune Responses
Share to Telomeres, Telomerase, and Senescence
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31558479
DOI: 10.1158/1078-0432.ccr-19-1614

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid TumorsPMID 31558479Read ↗

Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumorsSemantic proximity Read ↗

A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer.Semantic proximity Read ↗

Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung CancerSemantic proximity Read ↗

Activity of mRNA COVID-19 vaccines in patients with lymphoid malignanciesSemantic proximity Read ↗

Clinical research progress of telomerase targeted cancer immunotherapy: a literature reviewSemantic proximity Read ↗

Telomerase-based Cancer Therapeutics: A Review on their Clinical TrialsSemantic proximity Read ↗

Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapySemantic proximity Read ↗

Anti-Cancer Immunotherapies Targeting TelomeraseSemantic proximity Read ↗

DNA Immunotherapy for Recurrent Respiratory Papillomatosis (RRP): Phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107Semantic proximity Read ↗

Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trialSemantic proximity Read ↗

DNA-encoded bispecific T cell engagers and antibodies present long-term antitumor activitySemantic proximity Read ↗

Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: Results of a first-in-human Phase 1 trialSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.